Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLC011
MIFTS: 62

Pilocytic Astrocytoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pilocytic Astrocytoma

About this section

MalaCards integrated aliases for Pilocytic Astrocytoma:

Name: Pilocytic Astrocytoma 12 53 59 29 55 6 15 73
Juvenile Pilocytic Astrocytoma 53 73
Grade I Astrocytic Tumor 12
Piloid Astrocytoma 12

Characteristics:

Orphanet epidemiological data:

59
pilocytic astrocytoma
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4851
MeSH 44 D001254
NCIt 50 C4047
Orphanet 59 ORPHA251612
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 74 C0334583
UMLS 73 C0334583
Sources

Summaries for Pilocytic Astrocytoma

About this section
NIH Rare Diseases : 53 Pilocytic astrocytoma is an often benign, slow-growing tumor of the brain or spinal cord. The tumor may be in the form of a cyst and usually does not spread to nearby tissues. Symptoms vary depending upon the size and location of the tumor. Most symptoms result from increased pressure on the brain and include headaches, nausea, vomiting, balance problems, and vision abnormalities. The underlying cause of a pilocytic astrocytoma is unknown. It most commonly occurs in children and young adults, and in people with neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome, and tuberous sclerosis. This type of tumor can often be cured with surgery.

MalaCards based summary : Pilocytic Astrocytoma, also known as juvenile pilocytic astrocytoma, is related to pilocytic astrocytoma of cerebellum and juvenile pilocytic astrocytoma, and has symptoms including headache An important gene associated with Pilocytic Astrocytoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Vincristine and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include the brain, brain and spinal cord, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An astrocytoma that is characterized by cells that look like fibers when viewed under a microscope and is located in the brain.

Wikipedia : 76 Pilocytic astrocytoma or juvenile pilocytic astrocytoma or cystic cerebellar astrocytoma (and its... more...

Sources

Related Diseases for Pilocytic Astrocytoma

About this section

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 pilocytic astrocytoma of cerebellum 35.1 BRAF IDH1 KIAA1549 NF1
2 juvenile pilocytic astrocytoma 34.8 CDKN2A GFAP NF1 TIMP3 TP53
3 childhood pilocytic astrocytoma 34.0 KIAA1549 NF1
4 gliofibroma 31.4 GFAP NF1 TP53
5 pilomyxoid astrocytoma 31.3 GFAP KIAA1549 SYP
6 dysembryoplastic neuroepithelial tumor 31.3 GFAP IDH1 SYP
7 glioma 31.1 BRAF CDKN2A FGFR1 IDH1 NF1 TP53
8 ganglioglioma 31.1 BRAF GFAP SYP TP53
9 noonan syndrome 1 31.0 BRAF KRAS NF1 PTPN11 RAF1
10 anaplastic oligodendroglioma 30.8 CDKN2A GFAP MGMT
11 tanycytic ependymoma 30.7 GFAP OLIG2 SYP
12 glioblastoma 30.7 BRAF CDKN2A FGFR1 IDH1 MGMT TP53
13 adenocarcinoma 30.6 BRAF CDKN2A FGFR1 KRAS TP53
14 glioblastoma multiforme 30.6 CDKN2A GFAP IDH1 MGMT TP53
15 ependymoma 30.5 GFAP MGMT SYP TIMP3
16 obstructive hydrocephalus 30.4 GFAP NF1 SRGAP3 SYP
17 grade iii astrocytoma 30.1 APOD CDKN2A GFAP MGMT OLIG2 TP53
18 gliosarcoma 30.0 FGFR1 GFAP IDH1 MGMT TP53
19 pleomorphic xanthoastrocytoma 29.9 BRAF GFAP IDH1 MGMT SYP TP53
20 oligodendroglioma 29.6 CDKN2A GFAP IDH1 MGMT OLIG2 SOX10
21 medulloblastoma 29.1 FGFR1 GFAP IDH1 MGMT NTRK2 SYP
22 astrocytoma 11.2
23 hyperplastic polyposis syndrome 11.1 BRAF KRAS TP53
24 nevus of ota 11.1 BRAF TP53
25 frontal convexity meningioma 11.1 GFAP TP53
26 brain stem astrocytic neoplasm 11.1 CDKN2A TP53
27 spitz nevus 11.1 BRAF CDKN2A TP53
28 cerebellar astrocytoma 11.1 IDH1 KIAA1549 TP53
29 mature teratoma 11.1 BRAF KRAS TP53
30 syringocystadenoma papilliferum 11.1 BRAF GFAP KRAS
31 nasal cavity adenocarcinoma 11.1 CDKN2A KRAS TP53
32 rare adenocarcinoma of the breast 11.1 KRAS TP53
33 biliary tract neoplasm 11.1 CDKN2A KRAS TP53
34 lentigines 11.0 BRAF PTPN11 RAF1
35 barrett's adenocarcinoma 11.0 CDKN2A KRAS TP53
36 noonan syndrome with multiple lentigines 11.0 BRAF PTPN11 RAF1
37 mixed glioma 11.0 GFAP IDH1 TP53
38 gastrointestinal system benign neoplasm 11.0 CDKN2A KRAS TP53
39 bladder squamous cell carcinoma 11.0 BRAF CDKN2A TP53
40 bile duct adenocarcinoma 11.0 IDH1 KRAS TP53
41 skin squamous cell carcinoma 11.0 BRAF CDKN2A KRAS TP53
42 necrotizing sialometaplasia 11.0 CDKN2A GFAP TP53
43 autosomal dominant café au lait spots 11.0 NF1 PTPN11
44 intracranial chondrosarcoma 11.0 IDH1 TP53
45 gliomatosis cerebri 11.0 GFAP IDH1 TP53
46 differentiated thyroid carcinoma 11.0 BRAF CDKN2A KRAS TP53
47 cardiofaciocutaneous syndrome 1 11.0 BRAF KRAS PTPN11
48 endometrial adenocarcinoma 11.0 CDKN2A KRAS TP53
49 colorectal adenocarcinoma 11.0 BRAF KRAS TP53
50 leopard syndrome 10.9 BRAF NF1 PTPN11 RAF1

Graphical network of the top 20 diseases related to Pilocytic Astrocytoma:



Diseases related to Pilocytic Astrocytoma
Sources

Symptoms & Phenotypes for Pilocytic Astrocytoma

About this section

UMLS symptoms related to Pilocytic Astrocytoma:


headache

GenomeRNAi Phenotypes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

26 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.65 KRAS
2 Decreased viability GR00106-A-0 10.65 KRAS
3 Decreased viability GR00221-A-1 10.65 RAF1 NF1 NTRK2 KRAS CDKN2A FGFR1
4 Decreased viability GR00221-A-2 10.65 NF1 RAF1 NTRK2 KRAS FGFR1
5 Decreased viability GR00221-A-3 10.65 CDKN2A
6 Decreased viability GR00221-A-4 10.65 NF1 NTRK2 CDKN2A
7 Decreased viability GR00231-A 10.65 RAF1
8 Decreased viability GR00301-A 10.65 RAF1 KRAS
9 Decreased viability GR00381-A-1 10.65 KRAS
10 Decreased viability GR00402-S-2 10.65 NF1 RAF1 NTRK2 CDKN2A KRAS FGFR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.97 FGFR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.97 BRAF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.97 PTPN11
14 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.97 PTPN11
15 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.97 FGFR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.97 FGFR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.97 IDH1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.97 SRGAP3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.97 IDH1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.97 PTPN11 IDH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.97 IDH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.97 PTPN11 BRAF
23 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.97 SRGAP3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.97 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.97 FGFR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.97 IDH1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.97 BRAF
28 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.97 PTPN11
29 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.97 FGFR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.97 PTPN11
31 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.97 BRAF
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.97 SRGAP3
33 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.97 BRAF
34 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.97 SRGAP3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.97 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.97 BRAF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.97 SRGAP3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.97 PTPN11
39 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.97 IDH1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.97 SRGAP3 FGFR1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.97 SRGAP3 PTPN11 BRAF IDH1 FGFR1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.97 FGFR1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.97 PTPN11
44 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.97 FGFR1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.97 PTPN11
46 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.97 SRGAP3
47 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.97 FGFR1
48 Decreased viability in esophageal squamous lineage GR00235-A 9.9 SOX10 TIMP3 TP53 PTPN11 GFAP BRAF
49 Increased cell migration GR00055-A-3 9.26 NF1 SRGAP3 KRAS BRAF

MGI Mouse Phenotypes related to Pilocytic Astrocytoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.57 GFAP KIAA1549 KRAS GTF2I NTRK2 NF1
2 homeostasis/metabolism MP:0005376 10.47 IDH1 KIAA1549 GFAP KRAS MGMT NTRK2
3 cellular MP:0005384 10.44 GFAP GTF2I FGFR1 NTRK2 NF1 KRAS
4 growth/size/body region MP:0005378 10.43 IDH1 GFAP GTF2I FGFR1 NTRK2 KRAS
5 mortality/aging MP:0010768 10.43 IDH1 GFAP KRAS GTF2I MGMT NTRK2
6 cardiovascular system MP:0005385 10.38 FGFR1 GFAP GTF2I NF1 KRAS RAF1
7 endocrine/exocrine gland MP:0005379 10.38 KRAS GTF2I MGMT NTRK2 NF1 RAF1
8 nervous system MP:0003631 10.31 GFAP KRAS GTF2I NTRK2 NF1 RAF1
9 immune system MP:0005387 10.3 FGFR1 IDH1 KIAA1549 GFAP NF1 KRAS
10 embryo MP:0005380 10.27 GTF2I FGFR1 NF1 KRAS RAF1 PTPN11
11 digestive/alimentary MP:0005381 10.24 FGFR1 GFAP NF1 KRAS PTPN11 SOX10
12 integument MP:0010771 10.21 FGFR1 NF1 KRAS RAF1 PTPN11 SOX10
13 hearing/vestibular/ear MP:0005377 10.2 FGFR1 NTRK2 KRAS NF1 RAF1 PTPN11
14 muscle MP:0005369 10.2 GFAP KRAS NF1 RAF1 PTPN11 OLIG2
15 craniofacial MP:0005382 10.19 GTF2I FGFR1 NF1 KRAS RAF1 PTPN11
16 adipose tissue MP:0005375 10.16 KIAA1549 NTRK2 OLIG2 PTPN11 TIMP3 TP53
17 liver/biliary system MP:0005370 10.15 NF1 KRAS NTRK2 RAF1 PTPN11 TP53
18 neoplasm MP:0002006 10.13 KRAS MGMT NF1 RAF1 PTPN11 OLIG2
19 normal MP:0002873 10.1 GFAP KRAS GTF2I FGFR1 NTRK2 NF1
20 no phenotypic analysis MP:0003012 10.07 GTF2I FGFR1 MGMT KRAS OLIG2 RAF1
21 respiratory system MP:0005388 9.97 IDH1 KRAS MGMT NTRK2 NF1 OLIG2
22 pigmentation MP:0001186 9.86 KRAS NF1 PTPN11 TP53 TIMP3 SOX10
23 skeleton MP:0005390 9.7 FGFR1 IDH1 NTRK2 NF1 KRAS OLIG2
24 vision/eye MP:0005391 9.4 GFAP KRAS NTRK2 NF1 RAF1 PTPN11
Sources

Drugs & Therapeutics for Pilocytic Astrocytoma

About this section

Drugs for Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1 2068-78-2, 57-22-7 5978
2
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
3
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
4
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11 Alkylating Agents Phase 2, Phase 3,Phase 1
12 Dermatologic Agents Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
14 Analgesics Phase 3
15 Central Nervous System Depressants Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Central Nervous System Stimulants Phase 3,Phase 2
18 Cholinergic Agents Phase 3,Phase 2
19 Cholinesterase Inhibitors Phase 3,Phase 2
20 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
21 Narcotics Phase 3
22 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
23 Analgesics, Opioid Phase 3
24 Anesthetics Phase 3
25 Nootropic Agents Phase 3,Phase 2
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Peripheral Nervous System Agents Phase 3
29 Liver Extracts Phase 3,Phase 2,Phase 1
30 Antimitotic Agents Phase 2, Phase 3,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
32 Dopamine Agents Phase 3,Not Applicable
33
Histamine Phosphate Phase 3 51-74-1 65513
34 Serotonin Agents Phase 3
35 Serotonin Antagonists Phase 3
36 Histamine Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38 Neurotransmitter Uptake Inhibitors Phase 3
39 Dexmethylphenidate Hydrochloride Phase 3
40 Anti-Allergic Agents Phase 3
41 Dopamine Uptake Inhibitors Phase 3
42 Antipruritics Phase 3
43 Cola Nutraceutical Phase 3,Phase 1
44
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
45
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
47
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
48
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
49
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
6 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
7 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
8 Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
9 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
10 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
11 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
12 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
13 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
14 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
15 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
16 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
17 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
18 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
19 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
20 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
21 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
22 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
23 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
24 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
25 Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
26 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
27 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
28 Bevacizumab in Recurrent Grade II and III Glioma Active, not recruiting NCT01164189 Phase 2 Temozolomide
29 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
30 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
31 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
32 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
33 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
34 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
35 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
36 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
37 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
38 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
39 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
40 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
41 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
42 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
43 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
44 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
45 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003484 Phase 1 carmustine;irinotecan hydrochloride
46 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
47 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
48 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
49 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
50 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium

Search NIH Clinical Center for Pilocytic Astrocytoma

Sources

Genetic Tests for Pilocytic Astrocytoma

About this section

Genetic tests related to Pilocytic Astrocytoma:

# Genetic test Affiliating Genes
1 Pilocytic Astrocytoma 29
Sources

Anatomical Context for Pilocytic Astrocytoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Pilocytic Astrocytoma:

19
The Brain

MalaCards organs/tissues related to Pilocytic Astrocytoma:

41
Brain, Spinal Cord, Cerebellum, Liver, Pineal, Bone, Kidney
Sources

Publications for Pilocytic Astrocytoma

About this section

Articles related to Pilocytic Astrocytoma:

(show top 50) (show all 438)
# Title Authors Year
1
Absence of 1p/19q codeletion in oligodendroglioma-like areas of pilocytic astrocytomas. ( 29595124 )
2018
2
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
3
Supratentorial extension of large cerebellar pilocytic astrocytoma in adult. ( 29446978 )
2018
4
Reader response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807920 )
2018
5
Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma. ( 29629823 )
2018
6
Management and survival of adult patients with pilocytic astrocytoma in the National Cancer Database. ( 29427814 )
2018
7
Long-Term Remission of Recurrent Brainstem Pilocytic Astrocytoma with Neuraxis Dissemination Using Recombinant Human Endostatin After Failure of Vincristine and Carboplatin. ( 29203315 )
2018
8
Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. ( 29180079 )
2018
9
Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. ( 29171168 )
2018
10
An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. ( 29851180 )
2018
11
CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. ( 29804288 )
2018
12
Diagnostic accuracy of diffusion weighted imaging for differentiation of supratentorial pilocytic astrocytoma and pleomorphic xanthoastrocytoma. ( 29797290 )
2018
13
Pilocytic astrocytoma with spontaneous malignant transformation with intracranial and skeletal dissemination: case report and review of the literature. ( 29745267 )
2018
14
Dysembryoplastic neuroepithelial tumor-like pilocytic astrocytoma: A case report. ( 29768357 )
2018
15
Rare compound heterozygous variants in PNKP identified by whole exome sequencing in a German patient with ataxia-oculomotor apraxia 4 and pilocytic astrocytoma. ( 29498415 )
2018
16
Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage. ( 29569086 )
2018
17
Simultaneous supratentorial and infratentorial pilocytic astrocytoma in an adult patient with concurrent neurofibromatosis type 1 and HIV infection. ( 29908379 )
2018
18
Mitogen-activated protein kinase in gliosis and pilocytic astrocytoma. ( 29168690 )
2018
19
<i>FGFR1</i> tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. ( 29610389 )
2018
20
Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. ( 29330645 )
2018
21
Editors' note: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807919 )
2018
22
Pseudoprogression successfully treated with bevacizumab in a child with spinal pilocytic astrocytoma. ( 29804214 )
2018
23
Lacunar Stroke, Cavernous Angioma, and Fusiform Aneurysm Due to Irradiation for Pilocytic Astrocytoma-A Case Report. ( 29673614 )
2018
24
Intraorbital ancient pilocytic astrocytoma of the optic nerve in neurofibromatosis type 1 patient presenting with sudden ocular pain. ( 29511546 )
2018
25
Orbital tumor associated with a microphthalmic eye and colobomatous cleft: Pilocytic astrocytoma (glioma) or massive retinal gliosis. ( 29755278 )
2018
26
Circulating serum oncologic miRNA in pediatric juvenile pilocytic astrocytoma patients predicts mural nodule volume. ( 29911246 )
2018
27
Author response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807921 )
2018
28
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. ( 27718322 )
2017
29
Pilocytic astrocytoma mimicking cavernous angioma: Imaging features and histological characteristics. ( 28919136 )
2017
30
Pilocytic astrocytoma of the cerebellopontine angle mimicking vestibular schwannoma: report of a rare entity. ( 29278012 )
2017
31
Pilocytic astrocytoma: A rare presentation as intraventricular tumor. ( 28680735 )
2017
32
Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy. ( 28137267 )
2017
33
Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. ( 28960151 )
2017
34
Pilocytic Astrocytoma Enlargement Following Irradiation: Relapse or Pseudoprogression? ( 28367384 )
2017
35
Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. ( 28567590 )
2017
36
Midbrain Gliofibroma Presenting in Adulthood following &amp;quot;Cure&amp;quot; of a Childhood Intraventricular Pilocytic Astrocytoma. ( 28245445 )
2017
37
Hydrocephalus associated with spinal intramedullary pilocytic astrocytoma. ( 28484535 )
2017
38
Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. ( 28412241 )
2017
39
A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28448514 )
2017
40
Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29061673 )
2017
41
Isolated Trochlear Palsy Due to Pilocytic Astrocytoma Involving the Pineal Gland. ( 28831788 )
2017
42
Recurrent Optic Nerve Pilocytic Astrocytoma: A Rare Case. ( 28658822 )
2017
43
Exophytic bulbar pilocytic astrocytoma and post-operative cerebral salt wasting syndrome. ( 28478813 )
2017
44
A novel GIT2-BRAF fusion in pilocytic astrocytoma. ( 29141672 )
2017
45
Resection of a Pediatric Thalamic Juvenile Pilocytic Astrocytoma with Whole Brain Tractography. ( 29234572 )
2017
46
Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. ( 28468611 )
2017
47
A Case of Leptomeningeal Dissemination of Pilocytic Astrocytoma in a Child. ( 28446265 )
2017
48
Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence. ( 28388012 )
2017
49
Correction: A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28880959 )
2017
50
Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome. ( 28968151 )
2017
Sources

Variations for Pilocytic Astrocytoma

About this section

ClinVar genetic disease variations for Pilocytic Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
2 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh38 Chromosome 12, 25245348: 25245348

Copy number variations for Pilocytic Astrocytoma from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 38161 10 1 3000000 Gain DIP2C Pilocytic astrocytoma
2 40599 10 130600000 135534747 Loss DRD1IP Pilocytic astrocytoma
3 64537 12 129300000 133851895 Loss BCL7A Pilocytic astrocytoma
4 84233 14 24600000 33300000 Loss FOXG1B Pilocytic astrocytoma
5 97079 15 98500000 102531392 Loss LASS3 Pilocytic astrocytoma
6 112680 17 40811265 40819024 Loss TUBG2 Pilocytic astrocytoma
7 112684 17 40834631 40852011 Loss CNTNAP1 Pilocytic astrocytoma
8 220399 7 138200000 143100000 Amplification Pilocytic astrocytoma
9 227901 7 72200000 77500000 Loss BCL7B Pilocytic astrocytoma
10 230764 8 1 2200000 Loss Pilocytic astrocytoma
11 234563 8 136400000 146364022 Gain COL22A1 Pilocytic astrocytoma
12 234873 8 139900000 146364022 Gain CYHR1 Pilocytic astrocytoma
13 234878 8 139900000 146364022 Gain FOXH1 Pilocytic astrocytoma
14 234881 8 139900000 146364022 Gain GPT Pilocytic astrocytoma
15 234884 8 139900000 146364022 Gain KIFC2 Pilocytic astrocytoma
16 234886 8 139900000 146364022 Gain LRRC14 Pilocytic astrocytoma
17 234888 8 139900000 146364022 Gain LRRC24 Pilocytic astrocytoma
18 234890 8 139900000 146364022 Gain MFSD3 Pilocytic astrocytoma
19 234893 8 139900000 146364022 Gain PPP1R16A Pilocytic astrocytoma
20 234897 8 139900000 146364022 Gain RECQL4 Pilocytic astrocytoma
21 244900 9 1 2200000 Loss ANKRD15 Pilocytic astrocytoma
22 256191 9 9000000 28000000 Loss SH3GL2 Pilocytic astrocytoma
Sources

Expression for Pilocytic Astrocytoma

About this section
Search GEO for disease gene expression data for Pilocytic Astrocytoma.
Sources

Pathways for Pilocytic Astrocytoma

About this section

Pathways related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.86 BRAF CDKN2A FGFR1 GFAP KRAS NF1
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.35 BRAF FGFR1 KRAS NF1 PTPN11 RAF1
3
Phospholipase-C Pathway 64
Show member pathways
 13.05 BRAF FGFR1 KRAS NTRK2 RAF1 TIMP3
4
Pathways in cancer 37
12.83 BRAF CDKN2A FGFR1 KRAS RAF1 TP53
5
Endometrial cancer 37
Show member pathways
 12.83 BRAF CDKN2A FGFR1 KRAS PTPN11 RAF1
6
Gastric cancer 37
Show member pathways
 12.74 BRAF CDKN2A FGFR1 KRAS RAF1 TP53
7
Glioma 37
Show member pathways
 12.72 BRAF CDKN2A FGFR1 KRAS NF1 RAF1
8
MAPK signaling pathway 1 37
12.71 BRAF FGFR1 KRAS NF1 NTRK2 RAF1
9
Development HGF signaling pathway 22
Show member pathways
 12.67 BRAF KRAS NTRK2 PTPN11 RAF1 TP53
10
Ras signaling pathway 37
Show member pathways
 12.64 BRAF FGFR1 KRAS NF1 NTRK2 PTPN11
11
MicroRNAs in cancer 37
12.52 CDKN2A KRAS RAF1 TIMP3 TP53
12
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.49 BRAF FGFR1 KRAS RAF1 TP53
13
ErbB signaling pathway 1 37
Show member pathways
 12.47 BRAF KRAS PTPN11 RAF1 TP53
14
Apoptosis Pathway 72
Show member pathways
 12.42 FGFR1 KRAS NTRK2 TP53
15
CNTF Signaling 64
Show member pathways
 12.42 BRAF KRAS NTRK2 RAF1
16
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.37 BRAF KRAS NF1 PTPN11 RAF1
17
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.35 BRAF GTF2I KRAS PTPN11 RAF1
18
Signaling by moderate kinase activity BRAF mutants 66
Show member pathways
 12.29 BRAF KRAS NF1 RAF1
19
Signaling by FGFR2 66
Show member pathways
 12.27 BRAF FGFR1 KRAS PTPN11
20
VEGF Signaling Pathway 67 61
Show member pathways
 12.23 FGFR1 KRAS RAF1 TIMP3
21
Axon guidance 37
12.22 KRAS PTPN11 RAF1 SRGAP3
22
EGF/EGFR Signaling Pathway 1
12.19 BRAF KRAS PTPN11 RAF1
23
mTOR Pathway 72
Show member pathways
 12.17 BRAF KRAS RAF1 TP53
24
Cellular senescence (KEGG) 37
12.17 CDKN2A KRAS RAF1 TP53
25
Integrated Breast Cancer Pathway 1
12.15 BRAF KRAS NF1 TP53
26
NGF Pathway 64
Show member pathways
 12.14 BRAF KRAS RAF1 TP53
27
AKT Signaling Pathway 67
12.11 FGFR1 KRAS NTRK2 RAF1 TP53
28
Hepatitis C 37
12.06 BRAF KRAS RAF1 TP53
29
Oncogenic MAPK signaling 66
Show member pathways
 12.06 BRAF KIAA1549 KRAS NF1 RAF1
30
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.95 BRAF FGFR1 KRAS NTRK2 RAF1
31
Senescence and Autophagy in Cancer 1
11.94 BRAF CDKN2A RAF1 TP53
32
Neural Crest Differentiation 1
11.91 FGFR1 GFAP OLIG2 SOX10
33
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 11.89 BRAF KRAS PTPN11 RAF1 TIMP3 TP53
34
MAP Kinase Signaling 4
11.88 BRAF KRAS NF1 PTPN11 RAF1
35
Proteoglycans in cancer 37
11.8 BRAF FGFR1 KRAS PTPN11 RAF1 TIMP3
36
VEGF Pathway (Tocris) 72
Show member pathways
 11.77 BRAF FGFR1 KRAS RAF1
37
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.7 FGFR1 GFAP OLIG2 SOX10 SYP
38
Negative regulation of MAPK pathway 66
Show member pathways
 11.68 BRAF KRAS RAF1
39
Long-term depression 37
11.64 BRAF KRAS RAF1
40
Bladder cancer 37 1
11.58 BRAF CDKN2A KRAS RAF1 TP53
41
Aryl Hydrocarbon Receptor 1
11.53 KRAS NF1 RAF1
42
Central carbon metabolism in cancer 37
11.47 FGFR1 IDH1 KRAS RAF1 TP53
43
Vemurafenib Pathway, Pharmacodynamics 61
11.4 BRAF FGFR1 KRAS RAF1
44
BDNF-TrkB Signaling 1
11.35 BRAF KRAS NTRK2
45
G-protein signaling_K-RAS regulation pathway 22
11.21 BRAF KRAS RAF1
46
Glioblastoma Multiforme 64
11.21 BRAF CDKN2A KRAS MGMT NF1 RAF1
47
ERK Pathway in Huntingtons Disease 1
10.85 NTRK2 RAF1
Sources

GO Terms for Pilocytic Astrocytoma

About this section

Cellular components related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.56 BRAF CDKN2A IDH1 KRAS PTPN11 RAF1
2 cytoplasm GO:0005737 9.5 BRAF CDKN2A FGFR1 GFAP GTF2I IDH1

Biological processes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 BRAF FGFR1 MGMT NTRK2 RAF1 TP53
2 brain development GO:0007420 9.85 APOD FGFR1 NF1 PTPN11
3 MAPK cascade GO:0000165 9.77 BRAF FGFR1 KRAS NF1 RAF1
4 negative regulation of signal transduction GO:0009968 9.73 BRAF FGFR1 NTRK2 RAF1
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 BRAF NTRK2 RAF1
6 cellular response to drug GO:0035690 9.7 BRAF SOX10 TP53
7 long-term synaptic potentiation GO:0060291 9.67 BRAF GFAP NTRK2
8 visual learning GO:0008542 9.65 BRAF KRAS NF1
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 BRAF FGFR1 NTRK2 PTPN11 RAF1
10 oligodendrocyte differentiation GO:0048709 9.58 NTRK2 OLIG2 SOX10
11 regulation of synaptic transmission, GABAergic GO:0032228 9.57 KRAS NF1
12 replicative senescence GO:0090399 9.56 CDKN2A TP53
13 Bergmann glial cell differentiation GO:0060020 9.51 GFAP PTPN11
14 positive regulation of gene expression GO:0010628 9.43 BRAF CDKN2A KRAS NTRK2 SOX10 TP53
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.33 KRAS NF1 SYP
16 forebrain astrocyte development GO:0021897 9.32 KRAS NF1
17 Ras protein signal transduction GO:0007265 8.92 CDKN2A KRAS NF1 TP53

Molecular functions related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 BRAF FGFR1 GFAP IDH1 RAF1 SOX10
2 MAP kinase kinase kinase activity GO:0004709 9.26 BRAF FGFR1 NTRK2 RAF1
3 mitogen-activated protein kinase kinase binding GO:0031434 8.92 BRAF FGFR1 NTRK2 RAF1
Sources

Sources for Pilocytic Astrocytoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....